September is Childhood Cancer Awareness Month. 30,000 children in India and 10 times that number worldwide develop cancer every year. There is a lack of awareness and timely diagnosis to treat them. Sapien will be sharing the Indian cancer data it has throughout September, starting with colorectal cancer.

Patient Samples & Data – Powering Our Products & Services

August is Psoriasis awareness month so highlighting Sapien’s samples, data, services for R&D

Psoriasis has a disease prevalence of 0.44-2.8 per cent in India and 2 to 3 % worldwide. There are many gaps in research to fully understand the epidemiology, aetiology, association with comorbidities, environmental variations, that all hinder optimal delivery of healthcare services in a personalized manner. There is a need for better quality data on incidence and prevalence of psoriasis to understand better the size and distribution of the problem. http://www.apps.who.int/iris/bitstream/10665/

Sapien will be able to provide – Just what you need for your Psoriasis study

Sapien provides tailor-made biosample services adhering to IRB/IEC approved specimen collection protocols, and patient informed consent forms, and coding patient information to protect privacy.

  1. Sample types available – Blood, tissue punch samples, other biofluids.
  2. Ideal patient and sample requirements – Treated or treatment naïve, type of psoriasis, collection tubes/anticoagulant, processing e.g., blood to serum or plasma, PBMCs or DNA, quantity, molecular cellular IHC assays, H&E images
  3. Clinical Annotation – The exact type of data needed that you need – Demographic, lifestyle, diagnostic etc.
  4. Storage requirements – Specimen can be stored as per your protocol or shipped as per your instructions.

Whatever your future psoriasis research needs – An image study, AI, Digital pathology, data analysis, biomarker analysis, drugs screening – we are here to help you

  • Despite relatively high prevalence of psoriasis at 0.4 to 2.8 % in the Indian population and availability of many treatment options, India is behind in psoriasis disease management1.
  • Research done on specific ethnic backgrounds and data from one population is not a global solution. Hence it has been recommended by WHO’s global report on Psoriasis, that Psoriasis research should focus on specific ethnicity and therapeutics that are unique to a specific population 2.
  • There is an increasing demand for crucial studies addressing definitive curative therapies.

Hence, well-conducted research specific to Indian population considering the differences in genetic makeup, environmental influences and health care costs could go a long way in improving the healthcare services for the psoriasis patients 3.

  1. Thappa DM, Munisamy M. Research on psoriasis in India: Where do we stand? Indian J Med Res. 2017;146(2):147-149. doi: 10.4103/ijmr.IJMR_1296_17
  1. https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis;jsessionid=54912784D28C9F36ECCD45471AC5775B?sequence=1
  2. Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016; 7:471–80